HER2-Targeted Dendritic Cell Vaccine Shows Promise for Treating Patients with Early-Stage Breast Cancer

Researchers from the Moffitt Cancer Center in Tampa, Florida report that a dendritic cell vaccine that targets the HER2 protein on breast cancer cells is safe and effectively stimulates the immune system leading to regression of early-stage breast cancer.

 News Medical Net

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.